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Abstract
Background: The clinical course of Campylobacter infection varies in symptoms and severity depending on host
factors, virulence of the pathogen and initiated therapy. The type VI secretion system (T6SS) has been identified as
a novel virulence factor, which mediates contact-dependent injection of enzymes and toxins into competing
bacteria or host cells and facilitates the colonisation of a host organism. We aimed to compare the clinical course
of Campylobacter infection caused by strains with and without the T6SS and identify possible associations between
this putative virulence factor and the clinical manifestations of disease.
Methods: From April 2015 to January 2017, patients with detection of Campylobacter spp. were identified at the
University Hospital of Basel and the University Children’s Hospital of Basel and included in this case-control study.
Presence of the T6SS gene cluster was assayed by PCR targeting the hcp gene, confirmed with whole genome
sequencing. Pertinent clinical data was collected by medical record review. Differences in disease- and host-
characteristics between T6SS-positive (case) and –negative (control) were compared in a uni- and multi-variable
analysis. Hospital admission, antibiotic therapy, admission to intensive care unit, development of bacteraemia and
in-hospital mortality were considered as clinical endpoints.
Results: We identified 138 cases of Campylobacter jejuni infections and 18 cases of Campylobacter coli infections from a
paediatric and adult population. Analyses were focused on adult patients with C. jejuni (n = 119) of which 16.8% were
T6SS-positive. Comparisons between T6SS-positive and -negative C. jejuni isolates did not reveal significant differences
regarding clinical manifestations or course of disease. All clinical endpoints showed a similar distribution in both
groups. A higher score in the Charlson Comorbidity Index was associated with T6SS-positive C. jejuni isolates (p < 0.001)
and patients were more likely to have a solid organ transplant and to be under immunosuppressive therapy.
Conclusions: Our study does not provide evidence that T6SS is associated with a more severe clinical course.
Interestingly, T6SS-positive isolates are more commonly found in immunocompromised patients: an observation which
merits further investigation.
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Background
Infection with Campylobacter spp. is a worldwide leading
cause of diarrhoea, showing an increase in incidence over the
last decade in North America, Europe and Australia [1]. In
Switzerland, as in other European countries, campylobacter-
iosis is currently the most commonly reported food-borne
bacterial disease [2] with up to 70% of all cases attributable to
chicken consumption [3], thus posing a relevant public health
problem. In Switzerland, the incidence in 2017 was 85.4 cases
per 100,000 people [4] and the annual economic burden due
to laboratory-confirmed campylobacteriosis has recently been
estimated at around €8.3 million [5]. It is assumed that a
large number of additional cases go unreported [5].
The clinical course of campylobacteriosis varies in
symptoms and severity. Infection with Campylobacter
jejuni - the most frequently diagnosed species - is most
often characterised by acute diarrhoea, fever, and abdom-
inal pain [6]. In most cases self-limiting, symptoms typically
last from one day to a week, however, may persist for lon-
ger in 10–20% of patients and relapse may occur in another
5–10% [6]. The disease is occasionally further complicated
by bacteraemia and sepsis or by extra-gastrointestinal mani-
festations following enteric disease, such as reactive arthritis
and Guillain-Barré syndrome [6]. Complications and pro-
longed disease usually affect elderly or immunocomprom-
ised patients with comorbidities [1].
The clinical manifestation of infection with Campylo-
bacter spp. is determined by host factors such as
immune-competency, age, genetic background, and bac-
terial factors such as virulence of the pathogen, initial in-
fectious dose, and initiated therapy [6, 7]. Current
research has identified novel mechanisms that may con-
tribute to virulence and survival of Campylobacter spp. in
humans, such as the Type VI Secretion System (T6SS) [8],
one of several bacterial systems for protein secretion [9].
With a structure similar to the tail of the contractile bac-
teriophages [10], the T6SS allows the contact-dependent
secretion of effectors into other bacterial or host cells [11,
12]. The T6SS is encoded by a gene cluster of approx.17kb
comprising 13 genes [13]. One of the hallmark genes of
the T6SS gene cluster is hcp (encoding the secreted com-
ponent hemolysin co-regulated protein) [14], which has
been defined as a marker of a complete T6SS [15].
The expression of T6SS in C. jejuni has been demon-
strated to be of importance for host cell adhesion and in-
vasion in vitro: mutants with a defective secretion system
show an up to 50% reduced ability to adhere to and invade
colonic epithelial cells and macrophages [13]. Further-
more, in vivo studies show a higher persistence of C. jejuni
expressing T6SS, with the dynamics of T6SS-regulation
favouring colonisation of the colon [12, 13]. In polymicro-
bial environments such as the gastrointestinal tract, the
T6SS also presents an advantage by allowing the pathogen
to overcome the local microbiota [16].
In view of the diverse functionality of T6SS and extensive
in vitro/in vivo research, the secretion system may provide
a survival benefit for Campylobacter spp. contributing to
successful and persistent infection [17]. A possible connec-
tion between T6SS as a clinically relevant virulence factor
in Campylobacter spp. and manifestation of disease in
humans has been insufficiently studied so far. Harrison et
al. [15] found a correlation between T6SS-positive C. jejuni
strains and bloody diarrhoea, and accordingly more severe
disease, in a sample of 36 patients from Vietnam. A causal
relationship could, however, not be proven [15].
In this study, we aimed to compare the clinical course
of Campylobacter infection caused by strains with and
without T6SS in an observational case-control study,
and to identify possible associations between this viru-
lence factor and the clinical manifestations of disease.
Methods
Cases with detection of Campylobacter in any clinical iso-
late at the University Hospital Basel within the time period
from April 2015 to January 2017 were eligible for this ob-
servational case-control study. A total of 119 consecutive
C. jejuni and 15 C. coli bacteria were isolated. Coinfections
were excluded. Rare Campylobacter species such as C. fetus
(n = 2), C. upsaliensis (n = 2), and C. concisus (n = 1) were
also detected, but subsequently excluded from the analysis
due to the small sample size. Additionally, 22 Campylobac-
ter isolates were detected at the University Children’s Hos-
pital Basel during the same observation period. Due to
small sample size, these data were only analysed descrip-
tively and not included in the case-control study.
Patients and data collection
The study has been approved by the local ethical review
board (EKNZ, approval number 2016–01183). The med-
ical records of the included patients were retrospectively
reviewed. Data extraction was performed blinded for
T6SS status. Hospitalised cases included in this study
were admitted via the emergency unit. Outpatients were
most commonly treated in the emergency unit and in
some cases monitored for a maximum of one night.
The following data were systematically collected:
demographic characteristics, medical and travel history
as pertaining to the present infection. In addition, clin-
ical characteristics at presentation, characteristics of
diarrhoeal disease, and laboratory results at presentation,
as well as the requirement for antibiotic treatment, were
documented. Underlying diseases were recorded accord-
ing to the Charlson Comorbidity Index [18–21]. Regard-
ing treatment, fluid substitution and antibiotic therapy
(including duration and application) were recorded. In-
formation on the need for and duration of hospitalisa-
tion, need for ICU-stay and in-hospital mortality were
extracted. Microbiological data included identification to
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the species level and the antibiotic susceptibilities to
erythromycin and ciprofloxacin (μg/mL).
The following categorical factors were defined as pri-
mary clinical endpoints: need for hospital admission,
antibiotic therapy, intensive care unit (ICU) stay, devel-
opment of bacteraemia, and in-hospital mortality.
Isolate growth and identification
All routine clinical microbiology was performed in an
ISO/IEC 17025 accredited laboratory. Stool samples
were cultured in microaerobic conditions (5% O2, 10%
CO2 and 85% N2) on Campylosel agar plates (bioMér-
ieux, Marci I’Étoile, France) at 41 °C for 48 h. Bacterial
isolates were identified using Matrix Assisted Laser De-
sorption Ionization – Time of Flight mass spectrometry
using methods described by Bessède et al. [22] on a
Microflex LT mass spectrometer and MALDI Biotyper
Compass software v. 4.1.70 (Bruker Daltonics,
Germany). The value of “Score” ≥ 2.0 was accepted as a
measure for reliable species identification.
Minimal inhibitory concentration (MIC) determination
MICs for erythromycin and ciprofloxacin of each isolate
were determined by E-test (bioMérieux) and incubated
under microaerobic conditions on MHF (Müller Hinton
agar + 5% horse blood + 20mg/l β-NAD) agar plates
(bioMérieux) at 41 °C for 24 h. The interpretation of
MICs was performed according to EUCAST guidelines
(version 8.1; www.eucast.org).
Type VI secretion system (T6SS) PCR detection
PCR detection of the hcp gene as a locus representing the
T6SS in C. jejuni and C. coli isolates was performed [23].
We used C. jejuni subsp. jejuni strains from ATCC (Ref.
33560 and 43431) as positive controls. Briefly, the DNA of
cultured isolates was extracted using the DNA Bacterial
card on the EZ1 Advanced XL automated extraction sys-
tem (Qiagen, Hombrechtikon) using the manufacturer’s
protocol following a digestion step using proteinase K per-
formed for 10min at 56 °C and 10min at 95 °C. The PCR
used the following primers: Hcp_F 5′-CAAGCGGTG
CATCTACTGAA-3′, Hcp_R 5′-TAAGCTTTGCCCTC
TCTCCA-3′ and as a control the gltA gene gltA_F
5′-GCCCAAAGCCCATCAAGCGGA-3′, gltA_R 5′-GC
GCTTTGGGGTCATGCACA-3′. HotStarTaq (Qiagen)
was used for the PCR with a melting temperature of 57 °C.
PCR fragments (hcp 463 bp and gltA 142 bp) were detected
on a 2200 TapeStation instrument (Agilent, Santa Clara,
USA) using the D1000 ScreenTape assay (Agilent).
Whole genome sequencing (WGS)
Isolate details are given in Additional file 1: Table S1.
DNA was extracted as above. Library generation with
Nextera XT (Illumina, Cambridge, UK) was followed by
sequencing 2 × 300 bp on an Illumina Miseq platform.
Downstream analysis was performed in CLC Genomics
Workbench v 10.1.1 with read trimming and QC, followed
by coverage determination by mapping against the gen-
ome of NCTC11168 (accession number NC002163). All
genomes gave a mean coverage over 62x, up to 488x. The
presence of the T6SS was determined by mapping against
the well characterised T6SS locus in strain 414 (accession
number CM000855, locus tags C414_000040086-
C414_000040100) [13]. All isolates with reads mapping to
under 25% of the gene cluster, also with mean coverage of
the region lower than 1x, were considered as negative (n
= 103); those mapping to over 86% of the locus were con-
sidered to be positive (n = 21); and those mapping to 26–
41% of the locus considered as partial (n = 10). Read data
generated for this study can be found in the European Nu-
cleotide Archive (ENA, http://www.ebi.ac.uk/ena/) under
project number PRJEB30092.
Statistical methods
Descriptive analysis was performed with all data. For the
analysis of the clinical impact of T6SS, only adult patients
infected with C. jejuni were included into the statistical
model to obtain a more homogenous cohort. Median and
interquartile ranges are shown, unless otherwise indicated.
Disease and host characteristics were compared in a
univariate analysis between T6SS-positive (case) and
negative strains (controls). For the calculation of adjusted
odds ratios, a multivariable logistic regression model was
constructed using variables that were statistically
significantly associated with a positive T6SS status in the
univariate analysis. Results with p-values < 0.05 (two--
sided) were considered statistically significant.
Results
C. jejuni isolates are more often positive for T6SS than C.
coli
From April 2015 to January 2017, we identified a total of
119 cases of C. jejuni infection and 15 cases of C. coli in-
fection from an adult population. All cases were com-
munity acquired and no nosocomial infections occurred.
Six of 119 C. jejuni strains (5.0%) were isolated from
blood culture. In two patients with bacteraemia, stool
culture was also positive for the same species.
All isolates from the adult population (n= 134) were tested
for the presence of the T6SS, first by PCR targeting the hcp
gene, and also by WGS. Data agreed in all cases. Overall, 21
isolates (15.7%) were found to be T6SS positive. Regarding
species, 20/119 (16.8%) C. jejuni and 1/15 (6.7%) C. coli iso-
lates were found to be T6SS positive. In 10 cases, partial
mapping to the T6SS was observed, with reads mapping to
the locus tags C414_000040089 and C414_000040100, but
not to hcp (C414_000040085). Interestingly, mapping cover-
age to the T6SS in the positive isolates represented a relative
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coverage of 1–36% compared to mapping across the whole
genome (Additional file 1: Table S1).
Additionally, in a paediatric population, 19/22 (86.4%) C.
jejuni and 3/22 (13.6%) C. coli were isolated. The isolates
were screened by PCR for the hcp gene locus, which was
found in 3/19 (15.8%) C. jejuni strains. Due to the low fre-
quencies of isolates from paediatric patients and the obvi-
ous expected differences in both cohorts, we focused our
further analysis on bacterial isolates from adult patients.
Additional file 2: Table S2 provides the clinical characteris-
tics of children infected with Campylobacter spp.
T6SS positive C. jejuni isolates are associated with
resistance towards ciprofloxacin
All Campylobacter strains from the adult population
were tested for erythromycin and ciprofloxacin suscepti-
bility. Two of 119 C. jejuni (1.7%) and three of 15 C. coli
(20.0%) had resistant MICs for erythromycin. 72 of 119
C. jejuni (60.5%) and 10 of 15 C. coli (66.7%) had resist-
ant MICs for ciprofloxacin. All 20 T6SS-positive C.
jejuni strains were susceptible to erythromycin, whereas
17 of 20 T6SS-positive C. jejuni strains (85.0%) were re-
sistant to ciprofloxacin (Chi-squared, p = 0.01).
Clinical data
Clinical characteristics of infection in adult patients with C.
coli and C. jejuni are listed in Table 1. Infection with C. jejuni
manifested in 117/119 cases, and in all 15 C. coli cases, as
gastrointestinal disease with diarrhoea, often accompanied
by abdominal pain (68.1 and 46.7%, respectively) and vomit-
ing (28.6 and 20.0%, respectively). Patients also commonly
reported fever (52.1 and 46.7%, respectively).
In patients with C. jejuni infection, underlying diseases
were present in 47.9%. Malignancies (including solid
neoplasia, leukaemia and lymphoma) and diabetes mellitus
type 2 were identified as the leading comorbidities. Eleven
patients had an immunocompromised status due to a solid
organ transplant, allogenic haematologic stem cell
transplant (HSCT) or AIDS. The course of disease was un-
complicated in most cases. 61.3% of patients had to be hos-
pitalised. Two patients were admitted to ICU, one
bacteraemic patient died at the hospital. Table 2 compares
hospitalised patients with patients receiving outpatient care.
Hospitalised patients were older, showed a higher leucocyte
count and higher CRP-values, which are all indicators of a
more severely affected cohort. Creatinine clearance was
lower in hospitalised patients.
Comparisons between patients infected with C. jejuni
harbouring and not harbouring T6SS
Due to the low frequency of T6SS-positive C. coli strains,
only C. jejuni were included in the final statistical model.
We analysed the C. jejuni adult cohort (n = 119) with
respect to the T6SS status of each isolate, to ascertain pos-
sible associations with the virulence factor. Table 3 shows a
comparison of patients infected with T6SS-positive versus
T6SS-negative C. jejuni isolates, focusing on patient charac-
teristics and clinical course of disease. None of the defined
clinical endpoints was associated either with T6SS-positive
or negative C. jejuni isolates: 60.0% of patients with
T6SS-positive isolates and 61.6% with T6SS-negative iso-
lates were admitted to the hospital, respectively. Antibiotic
therapy was administered to 65.0% of patients infected with
T6SS-positive and in 60.6% of patients with T6SS-negative
isolates. One of 20 patients with a T6SS-positive isolate and
one of 99 patients with a T6SS-negative strain was admitted
to ICU. Of note, bacteraemia was present only in patients
infected with T6SS-negative strains (n = 6), leading to a
single patient death in hospital.
Patients infected with T6SS-positive C. jejuni isolates
had a higher score in the Charlson Comorbidity Index,
were more likely to have had a solid organ transplant, or
to be under immunosuppressive therapy as compared to
patients infected with T6SS-negative isolates. A higher co-
morbidity score remained associated with infection with a
T6SS-positive strain in multivariable analysis including
Table 1 Adult patient characteristics
Characteristics Patients with C. coli infection Patients with C. jejuni infection All adult patients
(n = 15) (n = 119) (n = 134)
Age (median years) 51 (26–80) 57 (33–74) 55 (33–74)
Male gender 7 (46.7) 74 (62.2) 81 (60.4)
Hospitalised patients 7 (46.7) 73 (61.3) 80 (59.7)
Duration of hospitalisation (median days) 0 (0–6) 1 (0–5) 1 (0–5)
Fever history (yes) 7 (46.7) 62 (52.1) 69 (51.5)
Bloody diarrhoea (yes) 2 (13.3) 21 (17.6) 23 (17.2)
Antibiotic therapy (yes) 9 (60.0) 73 (61.3) 82 (61.2)
Leucocytes (×10^9 /l) 8.5 (5.0–12.1) 8.6 (5.9–11.2) 8.5 (5.9–11.3)
C-reactive protein (mg/l) 69 (41–186) 66 (29–129) 68 (31–133)
Data are median (IQR) or n (%)
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the CCI, solid organ transplants and immunosuppressive
therapy in the final regression model (Table 4).
Discussion
This study adds to the growing amount of research on the
bacterial T6SS providing insight into its occurrence in
clinical Campylobacter spp. and examining its role in hu-
man infection.
While 15.7% of the isolates from the adult population were
positive for the complete T6SS locus, a proportion also carry
partial T6SS gene clusters, as has previously been noted [15,
24]. These were not identified by PCR primers targeting hcp,
meaning that the PCR of hcp is a valuable marker for a func-
tional T6SS [15]. That mean coverage of the T6SS is lower
than that across the genome may be a sequencing artefact
relating to the relatively low %G+C content of this locus, or
may indicate that the locus is lost from some bacteria during
culture.
The clinical characteristics of infection with Campylobac-
ter spp. in the study population are similar to those previ-
ously described by various authors [1, 6]. Infection with C.
jejuni and C. coli were clinically indistinguishable: both
manifested as acute gastroenteritis with a similar distribu-
tion in both species causing vomiting, abdominal pain,
bloody diarrhoea and fever history. Complications arose in
very few cases, with a single death attributable to invasive
campylobacteriosis. In view of epidemiologic studies report-
ing a peak incidence of Campylobacter infection in toddlers
and young adults [1, 25, 26], the median age of 55 in
patients in the present study seems relatively high. How-
ever, Schmutz et al. [27] describe a trend towards a higher
median age in Campylobacter infections in Switzerland. A
possible selection bias towards an older and sicker popula-
tion remains: 59.7% of all diagnosed patients required
hospital admission and antibiotic therapy was prescribed in
61.2% of cases. Furthermore, 5.0% of patients infected with
Table 2 Comparisons between adult patients hospitalised and receiving outpatient care with C. jejuni
Need for hospital admission Out-patient treatment p-value
(n = 73) (n = 46)
Male gender 48 (65.8) 26 (56.5)
Age (median years) 69 (49–81) 45 (27–63) < 0.001
Leucocytes (×10^9 /l) 9.2 (6.7–11.9) 7.6 (5.6–10.2) 0.05
C-reactive protein (mg/l) 84 (39–171) 43 (10–87) 0.001
Creatinine clearance (ml/min) 68 (41–95) 88 (71–108) 0.004
Data are median (IQR) or n (%). P values ≤0.05 are shown
Table 3 Comparisons between adult patients infected with T6SS-positive and T6SS-negative C. jejuni
T6SS-positive T6SS-negative p-value
(n = 20) (n = 99)
Baseline characteristics
Age (median years) 58 (46–77) 57 (31–74) n.s.
Male gender 13 (65.0) 61 (61.6) n.s.
Hospitalised patients 12 (60.0) 61 (61.6) n.s.
Duration of hospital stay (median days) 3 (0–5) 1 (0–5) n.s.
ICU stay (yes) 1 (5.0) 1 (1.0) n.s.
Comorbidities
Charlson Comorbidity Index 2 (1–5) 0 (0–1) < 0.001
Solid organ transplant 4 (20.0) 3 (3.0) 0.015
Immunosuppressant therapy 6 (30.0) 9 (9.1) 0.019
Clinical characteristics
Bacteraemia 0 (0.0) 6 (6.1) n.s.
Fever history (yes) 6 (30.0) 56 (56.6) 0.048
Bloody diarrhoea (yes) 2 (10.0) 19 (19.2) n.s.
Duration of diarrhoea (days) 6 (4–10) 6 (4–9) n.s.
Leucocytes (× 109/l) 8.5 (6.1–12.1) 8.7 (5.9–11.1) n.s.
Antibiotic therapy (yes) 13 (65.0) 60 (60.6) n.s.
Data are median (IQR) or n (%). P values ≤0.05 are shown. Only p-values of significant results were shown. n.s. non-significant
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C. jejuni had a positive blood culture, which is unusually
high considering population-based studies from Denmark
[28] and the USA [29]. These have described an incidence
of Campylobacter bacteraemia of less than 1% of all infec-
tions. Besides the aforementioned selection bias, this dis-
crepancy may also reflect the higher number of automatic
blood cultures performed in a hospital setting.
Various studies have investigated the epidemiology of
T6SS in C. jejuni. The T6SS seems to be more prevalent
in isolates from Asia and Egypt than Europe, with 60.6%
of human isolates T6SS-positive in Vietnam [15], 33.3%
in Thailand [15] and 57.6% in a large Egyptian paediatric
cohort [30]. European studies have shown a prevalence
of 2.6% in human isolates from the UK [15] and 14% in
chicken isolates from Spain [24]. The results of the
present study are in accordance with these studies in
that they uphold the large difference between Asian and
European strains. With a T6SS-prevalence of 16.8% in C.
jejuni the results are close to those from Spain [24], al-
though their strains were obtained from poultry and
sewerage water. Bleumink-Pluym et al. also identified a
T6SS-prevalence of about 10% in strains from various
sources such as human, chicken, swine, and cattle [14].
The reported prevalence of T6SS in C. coli reaches
from 18.0% in isolates from a paediatric cohort [30] to
56.1% in isolates from retail chicken [23]. Corcionivoschi
et al. [23] found a much higher percentage of
T6SS-positive C. coli in comparison with C. jejuni. As
they point out, only a small percentage of Campylobac-
ter infections in humans are caused by C. coli, whereas
the prevalence of C. coli and C. jejuni is almost equal in
their study [23]. The present study identified only one
functional T6SS among 15 C. coli isolates. The low
prevalence of 6.7% may be due to small sample size,
however: Sainato et al. [30] also recorded a relatively low
frequency of T6SS in C. coli (18%) in comparison to C.
jejuni (57.6%) in clinical isolates.
Our comparison between patients with T6SS-positive
and -negative C. jejuni isolates did not reveal a signifi-
cant difference in the clinical manifestations and the
course of disease. All variables defined as clinical end-
points (e.g. hospital admission, antibiotic therapy)
showed a similar distribution in both groups. These
findings agree with a recently published study examining
176 cases of infection with C. jejuni and 126 cases of in-
fection with C. coli in a paediatric cohort from Egypt
concerning the presence of the hcp gene [30]. The clin-
ical symptoms did not differ in severity between
T6SS-positive and –negative Campylobacter strains [30].
This stands in contrast to the findings of Harrison et al.
[15] of a positive association of T6SS-presence in C.
jejuni with bloody diarrhoea. Bleumink-Pluym et al. [14]
noted that 50% of their T6SS-positive strains were iso-
lated from blood, also suggesting an association with
more severe disease. The studies were performed with
36 and 8 C. jejuni strains, respectively, making it pos-
sible that the dissimilarity in findings is due to small
sample size and potentially other virulence factors.
We found a surprisingly stable association (p < 0.001)
with T6SS-positive strains for a higher score in the
Charlson Comorbidity Index, ascertained also in a multi-
variable model. Cancerous diseases and diabetes mellitus
type 2 were identified as the leading comorbidities.
These and other diseases assessed by the CCI show an
immunosuppressing effect in patients. It seems that pa-
tients with a higher morbidity, but also with an im-
munocompromised status are more susceptible to C.
jejuni strains harbouring a T6SS. The association of
T6SS-positive strains with allogenic haematopoietic stem
cell transplantation (HSCT), solid organ transplant and
immunosuppressant therapy (though not independently)
supports this hypothesis. In a study of Acinetobacter
baummanii isolates, Kim et al. [31] also found an associ-
ation between infection with T6SS-positive strains and
HSCT and immunosuppressant therapy. Our results sug-
gest a possible contribution of the T6SS to infection of
an immunocompromised and sickly host. The mechan-
ism, however, is not clear and should be further investi-
gated. The identified association may, however, be
influenced by selection bias towards an older and more
sickly population.
The rates of antibiotic resistance identified in the
present study are similar to those reported by other au-
thors [6, 32] with macrolide resistance higher in C. coli
(20.0%) than in C. jejuni (1.7%) and generally high resist-
ance rates for ciprofloxacin: 61.2% of all Campylobacter
Table 4 Uni- and multivariable logistic regression models
Crude Adjusteda
OR 95%CI p-value OR 95%CI p-value
Charlson Comorbidity Index 1.71 1.30–2.25 < 0.001 1.65 1.25–2.18 < 0.001
Solid organ transplant 8.08 1.65–39.54 0.010 1.82 0.19–17.83 0.608
Immunosuppression 4.33 1.34–14.05 0.015 2.41 0.41–14.10 0.328
Antacids 2.6 0.98–6.89 0.055
aCharlson Comorbidity Index, solid organ transplant and immunosuppressants were included in the final regression model
OR odds ratio, 95%CI 95% confidence interval
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isolates. Analysis of T6SS-positive C. jejuni strains
showed a significantly higher resistance rate for cipro-
floxacin. A possible explanation for this association may
be found in a correlation with clonal complexes analysed
by multi-locus sequencing typing. Kittl et al. [3], Collado
et al. [33] and Kovac et al. [34] examined the relation-
ship between ciprofloxacin-resistance and sequence
types in Campylobacter jejuni showing a significant as-
sociation with clonal complexes ST-21 [3, 33, 34],
ST-353 [33, 34], ST-48 [33] and ST-464 [3]. Kittl et al.
noted that the correlation was independent from the
host, suggesting that certain STs may develop more eas-
ily quinolone resistance [3]. Harrison et al. [15] found a
correlation between the T6SS and clonal complex
ST-353. It seems that clonal complexes showing higher
resistance for ciprofloxacin may also be those that are
associated with carrying the T6SS.
Our study has some important limitations: the overall
sample size is relatively small and for the statistical ana-
lysis we have only focused on C. jejuni isolates from
adult patients (n = 119). Also, a relative high proportion
of patients was hospitalised, which could reflect a more
severely ill and immunosuppressed patient population at
a tertiary hospital setting. Finally, we found only 20 C.
jejuni isolates with a T6SS locus.
Conclusions
Overall, our study does not provide evidence that the
T6SS is associated with a more severe clinical course in
Campylobacter jejuni. Interestingly, T6SS positive isolates
are more commonly found in immunocompromised pa-
tients: an observation which merits further investigation.
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Additional file 1: Table S1. Isolates and genome data. Description of
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